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Summary p2l protein (p21) inhibitor of cyclin-dependent kinases is a critical downstream effector in the p53-
specific pathway of growth control. p21 can also be induced by p53-independent pathways in relation to
terminal differentiation. We investigated p21 immunoreactivity in normal breast and in 91 breast carcinomas
[three in situ ductal carcinomas (DCIS) with microinfiltration and 88 infiltrating carcinomas, 17 of which with
an associated DCIS; 57 node negative and 34 node positive] with long-term follow-up (median= 58 months).
Seven additional breast carcinomas with known p53 gene mutations were investigated. In normal breast p21
expression was seen in the nuclei of rare luminal cells ofacinar structures, and in occasional myoepithelial cells.
Poorly differentiated DCIS showed high p21 expression, whereas well-differentiated DCIS tumours showed few
p21-reactive cells. p21 was seen in 82 (90%) infiltrating tumours; staining was heterogeneous; the percentage of
reactive nuclei ranged from 1% to 35%. High p21 expression (more than 10% of reactive cells) was seen in 24
(26%) cases, and was associated with high tumour grade (P=0.032); no associations were seen with tumour
size, metastases, oestrogen receptor status, MIBI expression and p53 expression. p21 expression in cases with
p53 gene mutations was low in six cases and high in one. High p21 expression was associated with short
relapse-free survival (P=0.003).
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p21 protein (p21), an inhibitor of cyclin-dependent kinases, is
the product of the WAFI gene (El-Deiry et al., 1993), also
known as CIPI (Harper et al., 1993), SDIJ (Noda et al.,
1994). p21 is a critical downstream effector in the p53-specific
pathway of growth control in mammalian cells. p53
expression in response to DNA-damaging agents promotes
the transcription of p21, which causes growth arrest through
inhibition of cyclin-dependent kinases (CDKs), which are
required for G, to S transition (El-Deiry et al., 1994; Xiong et
al., 1993). p21 can also be induced by p53-independent
pathways (Michieli et al., 1994; Johnson et al., 1994; Sheikh
et al., 1994), and its expression seems related to induction of
differentiation in several cell lines (Jiang et al., 1994;
Steinman et al., 1994; Halevy et al., 1995; Zhang et al.,
1995). p21 is also expressed in terminally differentiated cells
of embryonic and adult mouse tissues (Parker et al., 1995)
and in some human tissues (El-Diery et al., 1995; Marchetti
et al., 1996; Doglioni et al., 1996). It has therefore been
suggested that p21 may not only be responsible for the p53-
mediated growth arrest following DNA damage, but it may
also play an important role in maintenance of growth arrest
in terminally differentiated cells (Johnson et al., 1994; Halevy
et al., 1996). Heterogeneous p21 expression has been
observed in various human epithelial neoplasms (Marchetti
et al., 1995; Doglioni et al., 1996). In human lung non-small-
cell carcinomas, p21 expression at both immunohistochemical
and mRNA levels is related to tumoral differentiation and is
independent from p53 gene and protein alterations
(Marchetti et al., 1996). Conversely, in colorectal cancers,
p21 immunohistochemical expression is not related to tumour
grade and is inversely related to p53 protein overexpression
(Doglioni et al., 1996). These data suggest that p21
expression in human neoplasms may be differentially
regulated in a tissue-specific way.
In the present paper we investigated the expression of p21
at the immunohistochemical level in a series of 91 consecutive
breast carcinomas. The aim was to evaluate p21 expression in
relation to clinicopathological characteristics of the tumours,
oestrogen receptor (ER) status, expression of p53 protein and
of Ki67 proliferation related antigen, and relapse-free
survival. An additional group of seven breast carcinomas
with known p53 gene mutation was also evaluated to further
investigate the relations of p21 expression and p53
alterations.
Material and methods
Patients
A total of 91 consecutive cases of breast carcinomas were
investigated; patients had undergone surgery at the S. Chiara
Hospital of Trento, Italy (69 cases), or at the John Radcliffe
Hospital of Oxford, UK (22 cases), from January 1988 to
December 1991. Eligibility criteria were: histological diag-
nosis of breast carcinoma, level one or complete axillary
lymph node dissection, no distant metastasis, unilateral
tumour. Fifty-seven cases were node negative and 34 cases
were node positive (NI or N2). The median follow-up
duration of the patients was 58 months (range 9- 128). Node-
negative patients did not receive adjuvant therapy, whereas
node-positive patients were treated with systemic chemother-
apy or hormonotherapy and/or radiotherapy.
Tumour samples
Surgical samples were collected shortly after surgical removal,
and routinely fixed in buffered formalin for 24-48 h at room
temperature. Tissue specimens were routinely processed; cases
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were classified according to Azzopardi (1979) as follows: 74
infiltrating ductal carcinomas; two infiltrating lobular
carcinomas; five infiltrating tubular carcinomas; six muci-
nous carcinomas, one cribriform infiltrating carcinoma; and
three in situ ductal carcinomas (DCIS) with microinfiltration.
Invasive carcinomas were graded according to the modified
Bloom's grading system according to Elston and Ellis (1991).
In 25 cases there was abundant normal breast tissue
surrounding the neoplasms. In 17 cases the infiltrating
tumour was associated with a DCIS. The 20 cases of DCIS
(three DCIS with microinfiltration and 17 associated with an
overwhelming invasive componenent) were classified accord-
ing to Holland et al. (1994): four cases were well-
differentiated DCIS (including one solid, one cribriform and
two micropapillary), 11 were intermediately differentiated
DCIS (including five solid, three cribriform, two micro-
papillary, one clinging) and five cases were poorly differ-
entiated DCIS (including three comedo and two solid).
Seven additional breast carcinomas (four infiltrating
ductal carcinomas, two medullary carcinomas and one
infiltrating lobular carcinoma) with known p53 gene
mutations were investigated for p21 expression. These cases
were selected from a series of 148 previously published cases
that had been analysed for p53 mutations using the
polymerase chain reaction-single-strand conformation poly-
morphism (PCR-SSCP) technique and gene sequencing
(Marchetti et al., 1993). These seven cases have also been
proved to have no p21 gene alterations (Marchetti et al.,
1995).
Immunohistochemistry
p21 immunoreactivity was evaluated on paraffin sections of
primary tumours using the EAlO monoclonal antibody
(Oncogene Science, Cambridge, MA, USA), as described
previously (Marchetti et al., 1996; Doglioni et al., 1996).
Briefly, 4 ,UM paraffin sections were treated with the
microwave antigen retrieval system, incubated for 1 h at
room temperature with the primary antibody (1:100
dilution) and processed with the StreptABC technique,
using the Duett Kit (Dako, Glostrup, Denmark). Positive
controls were sections of lung tumours known to express
p21 at the mRNA and protein levels (Marchetti et al.,
1995). ER status was evaluated at the immunohistochemical
level using the ER1D5 antibody, as described previously
(Mauri et al., 1994; Veronese et al., 1995). p53 protein
immunoreactivity was assessed with the D07 monoclonal
antibody (Novocastra Laboratories, Newcastle upon Tyne,
UK) as described previously (Dei Tos et al., 1993). Positive
controls for p53 immunostaining were sections of breast
carcinomas known to overexpress p53 and sections of
atypical fibroxanthoma with known p53 gene mutation and
protein accumulation (Dei Tos et al., 1994). Twenty-one
cases were immunostained with the MIB1/Ki67 proliferation
antibodies related antigen, as described previously (Barbar-
eschi et al., 1994). Negative controls were obtained by
omitting primary antibodies.
Cells were considered positive for p21, ER and p53 only
when distinct nuclear staining was identified. The percentage
of immunoreactive nuclei was evaluated by scanning the
whole section at medium and high magnification, and by
counting at least 500 cells in the most densely stained tumour
areas.
Selected cases were processed with a double immunohis-
tochemical technique to stain p21 and p53 or p21 and MIBI,
using a StrepABC and an alkaline phosphatase anti-alkaline
phosphatase (APAAP) method, as described previously
(Doglioni et al., 1996). Briefly, the sections were first
immunostained with the first primary antibody followed by
a StreptABC technique with 3,3'-diaminobenzidine (DAB,
brown reaction product) or amino-ethyl-carbazole (AEC-red
reaction product) development; subsequently the sections
were treated in a microwave oven to block antibody cross-
reactivity (Lan et al., 1995) and immunostained with the
second primary antibody, using either a StreptABC or an
APAAP technique with nitroblue tetrazolium and 5-bromo-4-
chloro-3-indol phosphate (NBT/BCIP, blue reaction product)
or fast blue cytochemical staining. Negative controls were
obtained by omitting primary MAbs.
Statistical analysis
Statistical analysis was performed using the SAS system
(PROC FREQ, PROC LIFETEST and PROC PHREG), run
on an IBM-compatible personal computer. The association
between the variables was assessed using the chi-square and
Figure 1 Isolated p21-reactive cells in normal breast epithelial
cells (a) (arrows) and in cells showing apocrine metaplastic
changes (b). p21 immunostaining using the StrepABC technique
with DAB development and light haematoxylin counterstain
(original magnification (a) x 250 (b) x 400).
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Fisher exact tests. Relapse-free survival was estimated by the
method of Kaplan -Meier and differences between curves
were tested for statistical significance with the log-rank test.
Multivariate analysis was performed using the Cox propor-
tional hazard method in a stepwise manner.
Results
p2] immunohistochemistry
p21 immunoreactivity was always nuclear, with only rare
faint cytoplasmic staining. In normal breast tissue p21
immunostaining was limited to rare luminal cells of ducts
and acinar structures, and to occasional myoepithelial cells
(Figure la). The percentage of p21-reactive normal cells was
usually low (below 1% of the cells), but occasional acinar
structures showed a more pronounced p21 immunoreactivity
pattern. Staining intensity of p21-reactive normal cells was
usually low. Occasional p21-reactive cells were seen in areas
of adenosis and in rare apocrine cells lining cystic spaces
(Figure ib). Foamy cells within ectatic ducts were
occasionally p21 reactive.
DCIS showed heterogeneous p21 immunoreactivity. The
percentage of p21-reactive cells ranged from 0% to 38%, and
the median percentage value was 3% (Figure 2). Well-
differentiated DCIS showed a low percentage of p21-reacting
cells, the mean percentage of p21-reacting cells being 0.75%
(range 0-2%). Conversely, poorly differentiated DCIS
showed a high percentage of p21-positive cells, the median
percentage value being 23% (range 3-38%). In intermedi-
ately differentiated DCIS, the median value of p21-reactive
cells was 6% (range 0-20). Subdividing the cases of DCIS on
the basis of the median value of the percentage of p21-
reactive cells, a clear difference was seen between the three
groups of lesions (a formal statistical analysis could not be
performed owing to the small number of cases) (Table I).
In the overall series of breast carcinomas, p21-reactive cells
were seen in 82 (90%) cases. Staining intensity was variable and
heterogeneous (Figure 3). Frequently a mixture ofstrongly and
faintly stained cells was observed, but only clearly positive cells
were considered positive. The percentage ofp21-reactive nuclei
ranged from 0% to 50% of tumour cells; mean+s.d. and
median percentage of p21-reactive cells were 7.6+9.6 and 3.
Twenty-four (26%) cases showing strong p21 immunoreactiv-
ity (more than 10% ofreactive tumourcells) wereconsidered as
expressing high levels ofp21. p21 immunoreactivity was seen in
all types of infiltrating carcinomas. In some high-grade
carcinomas, p21 was strongly expressed in huge atypical
nuclei. A statistically significant association trend was seen
between high p21 expression and high histological grade
(P=0.032). No association could be seen between high p21
expression and any of the other pathological and biological
parameters examined (Table II).
Immunohistochemical staining of the cases with known
p53 gene mutation showed that p21 immunohistochemical
expression was low in six cases, and high in one case. This
case with high p21 expression showed p53 overexpression
(immunostaining in more than 90% of tumour cells) and
presented p53 gene mutation at codon 273 (exon 8).
In the stromal component of several tumours, p21
immunoreactivity was seen in occasional fibroblast and rare
lymphoid cells.
ER nuclear immunoreactivity was seen in 42 (46%)
carcinomas. Thirty-four (37%) cases with more than 10%
of reactive nuclei were considered as having a positive ER
status. p53 immunoreactivity was seen in 41 (45%) cases:
staining was always nuclear and the percentage of p53-
reactive nuclei ranged from 0% to 95%. Fourteen (15%)
cases with more than 15% of p53-reactive nuclei were
considered as overexpressing p53.
Cases with high p53 and p21 expression were investigated
using double immunostaining: most nuclei were intensely blue
or brown (blue or red, depending upon the immunostaining
technique) (Figure 4a) but some nuclei showed intermediate
a
b
c
Figure 2 p21 immunoreactivity in DCIS: p21-reactive cells are
few in well-diffentiated and irftermediately differentiated DCIS (a,
b), whereas in poorly differentiated DCIS (comedo type) they are
abundant and strongly reactive (c); p21 immunostaining using the
StrepABC technique with DAB development and light haematox-
ylin counterstain (original magnification x400).
colours, suggesting that some cells can accumulate both gene
products (Figure 4b). Double immunostaining for p21 and
MIBI showed that the two antigens were mutually exclusive
(Figure 5).
Clinical outcome of the patients
Only relapse-free survival (RFS) was evaluated in the present
study as the number of deaths due to disease progression did
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Table I Relations between histological types of DCIS [according to
Holland et al. (1994)] and p21 expression
Histological type Low p21 expressiona High p21 expression
Type 1 4 (100%) 0 (0%)
(well differentiated)
Type 2 4 (36%) 7 (64%)
(moderately differentiated)
Type 3 0 (0%) 5 (100%)
(poorly differentiated)
ap21 expression was considered low ifthe percentage ofp21-reactive
nuclei was less than the median value of 3%.
Table II Relations between p21 expression and biological and
clinical variables in breast carcinomas
Low p21 expressiona High p21 expression
(%) (%)
Histology
Ductal
Otherb
Tumour size
<20mm
>20mm
52 (71)
15 (83)
37 (76)
30 (711
22 (29)
3 (17)
NSC
12 (24)
12 (29)
NS
Nodal status
Positive (N1,N2)
Negative (NO)
Gradingd
GI
G2
G3
ER statuse
ER positive
ER negative
p53 expressionf
p53 positive
p53 negative
Figure 3 Examples of breast carcinomas with different
percentages of p21-reactive cells. (a) Grade I infiltrating ductal
carcinoma with less than 1% of reactive 'cells. (b) Grade 2
infiltrating ductal carcinoma with 5% of reactive cells. (c) Grade 3
infiltrating ductal carcinoma with strong p21 reactivity in 18% of
tumour cells. p21 immunostaining using the StrepABC technique
with DAB development and light haematoxylin counterstain
(original magnification x 250).
MIBI expressiong
low MIBI 10 (63) 6 (37)
high MIBI 11 (69) 5 (31)
NS
aCases are considered to have low p21 expression when p21-labelled
nuclei are < 10%, and are considered with high expression when more
than 10% of the nuclei are p21 reactive. bIncluding lobular, tubular,
mucinous, cribriform infiltrating carcinomas and DCIs with micro-
infiltration. 'Not statistically significant. dGrading not performed in
three DCIS with microinfiltration and in one infiltrating ductal
carcinoma whose morphology was not well preserved. eER status was
considered positive if at least 10% of tumour cells showed nuclear
immunoreactivity. fCases with more than 15% p53-positive tumour
cells were considered as overexpressing p53. 5MIB1 immunostaining
data were available for only 32 cases of node-negative breast
carcinomas; MIBI labelling was considered low if the percentage of
reactingcells was below the median value of 15%; MIBI labelling was
considered high ifthe percentage ofreacting cells was > to the median
value.
not allow a reliable statistical analysis. Disease relapses were
seen in 14 out of 57 node-negative patients and in 13 out of
34 node-positive patients.
At univariate analysis high p21 expression (more than
10% of reactive cells) proved to be statistically related to
short RFS (Figure 6, P=0.003 log-rank test). Besides p21
expression, large tumour size, presence of lymph node
metastases, negative oestrogen receptor status and high
grading were also significantly predictive for short RFS
(Table III).
Multivariate analysis of the above variables has been
performed using three different models. In the first one all
variables were dichotomised as shown in Table III: using this
model the only independent predictors for short RFS were
large tumour size and high p21 expression (P=0.0065, risk
ratio 3.072 and P=0.0061, risk ratio 2.885 respectively). A
second model was fitted forcing the variable nodal status to
be added to the model, with the aim of considering its
potential influence: using this model large tumour size and
high p21 expression were the only independent predictors for
short RFS (P=0.0061, risk ratio 3.089 and P=0.0089, risk
ratio 2.757 respectively), whereas nodal status was not far
from significance (P=0.0887, risk ratio 2.002). A third model
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a
b
Figure 4 Double immunostaining for p21 (brown) and p53
(blue) in a case of infiltrating ductal carcinoma with known p53
gene mutation in exon 8. p21 immunoreactivity was low (5% of
labelled nuclei) whereas p53 was diffuse and homogeneous. Some
nuclei are golden brown as they express only p21, and others are
dark blue as they express only p53; there are however also some
other nuclei that show an intermediate brownish-blue colour,
suggesting that they express both antigens. p21 immunostaining
using the StrepABC technique with DAB (brown) development;
p53 immunostaining with StrepABC technique and NBT (blue)
development (original magnification x 400).
was used, considering the grading as a numerical variable;
using this latter model the only independent predictors for
short RFS were grading and nodal status (P=0.0065, risk
ratio 2.522 and P=0.0409, risk ratio 2.420), while p21 was
excluded with a P-value of 0.1942. The above different results
obtained with different multivariate analysis models, suggest
that the effect of p21 may be at least partially dependent on
its strong association with grading. However, these data are
to be considered as preliminary as the small and hetero-
geneous number of cases in the present series may bias the
survival analysis (Figures 7 and 8).
Discussion
The p21 inhibitor of cyclin-dependent kinases is involved in
terminal differentiation of several cell systems, and in p53-
dependent inhibition of cell cycle progression (El-Deiry et al.,
1993; 1994; 1995; Noda et al., 1994; Xiong et al., 1993;
Michieli et al., 1994; Parker et al., 1995; Halevy et al., 1995).
Here we present evidence that in normal breast epithelium
p21 is expressed in rare (<1%) luminal cells of ducts and
acinar structures, and in occasional myoepithelial cells,
Figure 5 Double immunostaining for p21 (brown) and MIBI
(blue) in a case of DCIS (a) and in an infiltrating ductal
carcinoma (b). p21 and MIBI immunoreactivity are mutually
exclusive. p21 immunostaining using the StrepABC technique
with DAB (brown) development; MIBI immunostaining with
StrepABC technique and NBT (blue) development (original
magnification x 400).
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Figure 6 RFS curves for the group of 67 patients with low p21
expression (-) and the group of 24 patients with high p21
expression (- - -). Log-rank test, P=0.003.
Table III Relapse-free survival analysis
Variable P-value (log-rank test)
Tumour size <20 vs >20mm 0.003
Grading 1 plus 2 vs 3 0.01
Nodal status Positive vs negative 0.03
Histotype IDC vs other 0.03
ER Positive vs negative 0.048
p53 Positive vs negative 0.13
p21 <10 vs >10 0.003
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Figure 7 RFS curves for the group of 37 patients with small
tumours (<20mm) and low p21 expression (-), the group of 12
patients with small tumours and high p21 expression ( - -), the
group of 12 patients with large tumours and high p21 expression
( - - ), the group of 30 patients with large tumours and low
p21 expression (- - -). Log-rank test, P=0.0002.
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Figure 8 RFS curves in the group of 44 patients without
metastases and low p2l expression (-), in the group of 13
patients without metastases and high p21 expression ( - ), in
the group of 11 patients with metastases and high p21 expression
( - - ), in the group of 23 patients with metastases and low
p21 expression (- - -). Log-rank test, P=0.007.
whereas most epithelial cells are unreactive. This is at
variance with other human epithelial systems, such as the
colonic epithelium, where most cells in the upper third of the
glandular criptae and in surface epithelium (i.e. maturing and
terminally differentiated cells) are p21 reactive (Doglioni et
al., 1996; El-Deiry et al., 1995). It is tempting to hypothesise
that these different patterns of p21 expression may reflect
different mechanisms regulating cell proliferation, differentia-
tion, quiescence and apoptosis in different epithelial systems
(El-Deiry et al., 1995). The differences in p21 reactivity in
breast and colonic epithelium may indeed be related to their
different physiological properties. Breast epithelial cells have
a low proliferation and apoptotic rate, which reach a peak
toward the end of the menstrual cycle and are influenced by
rhythmical hormonal and/or growth factor changes during
the menstrual cycle (Ferguson and Anderson, 1981; Going et
al., 1988; Sabourin et al., 1994); conversely, colonic epithelial
cells have high turnover, with a continuous high proliferation
and cell loss rate (Levine and Haggit, 1992). Assuming that
p21 expression is related to cell differentiation and exit from
the cell cycle (Johnson et al., 1994; Halevy et al., 1995; El-
Deiry et al., 1995), it might be hypothesised that in the low-
turnover breast epithelial system, the low percentage of p21-
positive maturing cells parallels the low percentage of
proliferating and dying cells; conversely in the high-turnover
colonic epithelium, the percentage of p21-positive maturing
cells parallels the high percentage of proliferating and dying
cells. There are indeed several other differences in the
expression and regulation of genes involved in proliferation
and apoptosis in breast and colonic epithelium. For example,
Bcl-2 gene product, which is known to prevent the apoptotic
cascade, is widely expressed in normal breast epithelium,
whereas it is confined to only a few cells in the deeper
portions of colonic criptae (Sinicrope et al., 1995; Sabourin et
al., 1994; Doglioni et al., 1994; Gasparini et al., 1995).
p21/WAF1 expression in breast carcinoma
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In DCIS high p21 expression is more frequent in high-
grade lesions characterised by the presence of abundant
apoptotic bodies and by a typical pattern of central cell
death. Cell death in these types of DCIS could be related to
ischaemia, due to cell growth in the absence of neoangiogen-
esis. It is tempting to hypothesise that the ischaemia-
dependent growth arrest of DCIS cells could be accom-
plished by induction of p21. Indeed some of the autocrine/
paracrine factors with growth-inhibitory properties, such as
transforming growth factor (TGF)-,B1 (Gorsch et al., 1992;
Bursh et al., 1993), may also induce p21 expression as shown
in some in vitro epithelial systems (Datto et al., 1995).
Our present data on infiltrating breast carcinoma suggest
that p21 altered expression may be of pathogenetic relevance,
high p21 expression being associated with tumour progres-
sion.
Several mechanisms may be responsible for p21 altered
induction and heterogeneous expression at the immunohisto-
chemical level. Alterations of the WAFJ/CIPJ gene could be
one of these mechanisms, but to date no WAFI/CIPI gene
mutations have been reported in breast carcinomas
(Marchetti et al., 1995; Shiohara et al., 1994). Alterations
in the p21 induction pathway could be an alternative
mechanisms. p21 may be induced by wild-type p53 (El-
Deiry et al., 1994; Xiong et al., 1993): breast cancer cell lines
expressing wild-type p53 gene constitutively express 26 to 33-
fold higher p21 mRNA levels than cells harbouring the
mutant p53 gene (Sheikh et al., 1994). It could be
hypothesised that heterogeneous p21 expression at the
immunohistochemical level may reflect different p53 func-
tional status, high p21 expression being related to normal or
increased p53 function, and low p21 expression being related
to inactivation of p53 function. This mechanism has indeed
been hypothesised to explain p21 expression in colonic
carcinomas (Doglioni et al., 1996; El-Deiry et al., 1995).
However, in the present series of cases no definite relation
was seen between p21 expression and p53 immunohistochem-
ical alterations. Cases with low p21 and p53 expression could
be explained on the basis of the above hypothesis. However
there were cases with concurrent high p21 and p53
expression: as p53 overexpression is almost always due to
p53 gene mutation and possibly p53 function inactivation, it
may be hypothesised that p53-independent mechanisms may
indeed by responsible for p21 expression in breast
carcinomas. These data are in keeping with the findings in
lung carcinomas of the non-small-cell type, where p21
expression is indeed independent from p53 gene alterations
and p53 protein expression (Marchetti et al., 1995).
p21 heterogeneous expression could be related to the p53-
independent p21 transcription pathway related to terminal
differentiation. Expression of p21 (at mRNA and protein
levels) has indeed been demonstrated during induction of
differentiation of several tumour cell lines (Jiang et al., 1994;
Steinman et al., 1994). Moreover, in lung carcinomas high
p21 expression, at immunohistochemical and mRNA levels, is
related to tumour differentiation, both in terms of global
differentiation of the tumours and in terms of immunoloca-
lisation of p21 in foci of more pronounced differentiation
within single tumours (Marchetti et al., 1996). However, in
the present series of breast carcinomas high p21 expression
was not associated with tumour differentiation: on the
contrary, there was a trend for less differentiated tumours
to express high levels of p21. An hypothesis to explain such
inverse association could be related to the fact that
histological grade is a function of nuclear atypia, which in
some cases could be related to the age of the cells, and in
several cell systems p21 expression increases in an age-
dependent way (Tahara et al., 1995). Moreover, recent in
vitro data suggest that cellular atypia can be associated with
high p21 expression (Sheikh et al., 1995): another attractive
hypothesis concerns the possible induction of p21 by TGF-
/B1, which is known to be associated with disease progression
in breast carcinoma (Bursch et al., 1993; Datto et al., 1995).
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puzzling: at the single cell level p21 and MIB1 are mutually
exclusive, but no definite relation was seen examing p21 and
MIBl labelling indexes. p21 expression is indeed related to
growth arrest (El-Deiry et al.. 1995). and larger studies
should further investigate the relations between p21
expression and proliferation markers, such as MIB1 nuclear
proteins expressed in quiescent cells. such as statin (Ansari et
al.. 1993; Palanca-Wessels et al.. 1994) or other inhibitors of
cycin-dependent kinases, such as p27.
Much more has to be learned concerning the role of p21
expression in breast carcinoma. However, regardless of the
complexities of the molecular pathways that are responsible
for heterogeneity of p21 expression in breast carcinoma. our
preliminary data suggest that its evaluation could be of
possible prognostic value, possibly adding information to
that obtained from conventional prognostic parameters.
Moreover, as p21 is an important downstream effector in
the p53-specific growth arrest pathway in response to DNA-
damaging agents (El-Deiry et al.. 1994: Xiong et al.. 1993). it
is tempting to hypothesise that its heterogeneous expression
in tumours may be of relevance concerning the possible
therapeutic effects of anti-cancer drugs and radiotherapy that
induce DNA damage and or tnigger apoptosis.
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